Angle plc AGL

This company provides technology to medical researchers that lets them capture rare cells.

This one really is a bit of a secret. Signed up to plus for this and 4d Pharma. Check them out, liquid biopsy that detects live cancer cells from a blood test, potentially making personalised cancer treatments possible. Currently in talks with US FDA

1 Like

Seeing nice rise here. Still not too late for a long hold. Nice video at bottom of the link

1 Like

Thanks for the link, impressive stuff, I can see this doing very well long term, Up 29% in the last month !

How likely is the fda approval please? Does anyone know?

I guessing it’s already priced in but a short rise should be possible.

Doing well here on a down day

Just announced major contract and

still waiting for FDA approval hopefully H2 2021

Angle PLC Announces First Large-Scale Pharma Services Contract Secured

Published: Apr 16, 2021

  • Contract Worth Up to US$1.2 Million With Potential for Further Contracts From the Same Customer
  • Parsortix System Being Utilised in Cancer Drug Trials for Liquid Biopsy Longitudinal Monitoring Which Is Not Possible With Tissue Biopsies

GUILDFORD, UK / ACCESSWIRE / April 16, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that the Company has secured its first large-scale pharma services contract. The customer, a pharma company with numerous cancer drugs under development and revenues exceeding US$1 billion per annum, has selected ANGLE’s Parsortix® system to undertake longitudinal monitoring (i.e. before, during and after drug intervention) of patients in three separate global clinical trials in prostate cancer and other locally advanced and metastatic solid tumours.

The contract is expected to be worth up to US$1.2 million over some 18 months. The work relates to a large Phase III prostate cancer study and two smaller Phase I studies. The Phase I studies, if successful, could progress to larger Phase II studies and, if successful, much larger Phase III studies.

The services cover the capture, harvest and analysis of circulating tumor cells (CTCs) and CTC clusters. Samples are being shipped from multiple study centres to ANGLE’s clinical laboratories in the UK and United States for analysis using the Parsortix system.

The contract represents the first large-scale adoption of the Parsortix system for processing patient blood samples to help inform decision making in cancer drug trials. Importantly, the customer recognises the advantage in capturing mesenchymal as well as epithelial cancer cells and the importance that CTC clusters as well as single CTCs may have in the progression of disease, metastasis, and drug resistance.

The Parsortix liquid biopsy has particular advantages in capturing intact cancer cells including mesenchymal cells and clusters and provides the opportunity for longitudinal testing in a clinical setting, which is not possible with tissue biopsy. ANGLE believes that longitudinal monitoring of CTCs will prove highly attractive to the pharma industry looking for new insights in cancer drug trials.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

“We are delighted to have contracted with a pharma company developing numerous cancer drugs and look forward to working closely with them on their trials. ANGLE believes that there is a substantial business opportunity in providing services to pharma and biotech customers to support cancer drug trials. This contract demonstrates that our investment in clinical laboratories and a pharma services business, a key use of proceeds from our fundraising in October 2020, is already delivering. We look forward to announcing further progress on the expansion of this important business area for ANGLE in due course.”

https://webcast.openbriefing.com/angle-apr21/player/?player_id=42822

Excellent presentation from CEO for Prelim Results for YE 31/12/20

FDA SUBSTANTIVE REVIEW PROGRESSING

LAUNCH OF CLINICAL LABORATORY SERVICES

FIRST LARGE-SCALE CONTRACT WITH PHARMA CUSTOMER USING THE PARSORTIX SYSTEM IN CLINICAL TRIALS

PATIENT ENROLMENT COMPLETED IN OVARIAN CANCER CLINICAL VERIFICATION STUDY

overnight they raised £20m at a 7% discount

edit - my emphasis

Friday 25 June 2021

ANGLE plc

(“ANGLE” or the “Company”)

Result of Accelerated Bookbuild

Funds will allow the Company to pursue major prostate opportunity

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that, further to the announcement made yesterday, the Company has successfully raised gross proceeds of GBP20.0 million by conditionally placing 17,241,380 Placing Shares at a price of 116 pence per New Ordinary Share with new and existing investors.

The Issue Price represents a discount of approximately 6.83 per cent. to the closing mid-market price of an Ordinary Share of 124.50 pence on 23 June 2021. The Placing Shares represent approximately 7.40 per cent. of the Company’s Enlarged Issued Share Capital.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"We would like to thank our shareholders for their continued strong support and welcome new shareholders to the ANGLE register. The proceeds from this Placing will enable ANGLE to add to the current momentum in the commercialisation process of our Parsortix system and open up new market opportunities in Prostate Cancer diagnosis, an area of significant medical need. ANGLE looks forward to announcing further progress on multiple fronts in H2 CY21, including the prospect of FDA clearance for the Parsortix platform."

Use of Proceeds:

Prostate cancer opportunity GBP7m Building senior management team in the United States GBP3m ------- Assay development capability GBP2m ------- Ongoing operations for breast and ovarian cancers and strengthen balance sheet for pharma GBP8m services ------- Total GBP20m -------